Stay updated with breaking news from Tryp Therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital (MGH) on the effects of psilocybin-assisted psychotherapy for adults with Irritable B
Tryp Therapeutics’ TRYPF latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at…
Enables Potentially Scalable Model For The Broad Roll-Out of Psychedelic Treatments Company Will Host Investor Update Tuesday, October 4th ...
Is the Psychedelic Industry Following in the Footsteps of GW Pharma? By IBT Contributor Is the Psychedelic Industry Following in the Footsteps of GW Pharma Photo: Pixabay Recently, it was announced that the cannabis industry titan, GW Pharmaceuticals , was being acquired by Jazz Pharmaceuticals for $7.2 billion. Looking back to May of 2013 when GW first went public, it was trading at $8.90 - a mere fraction of its current market valuation of over $215 per share. At this time, the thought that the small cannabidiol company would later be the target of a 10-figure acquisition was ...